{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:29:35Z","timestamp":1782602975161,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.transproceed.2021.03.008","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T01:05:38Z","timestamp":1616029538000},"page":"1194-1201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy"],"prefix":"10.1016","volume":"53","author":[{"given":"Karolina","family":"K\u0119dzierska-Kapuza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Zieli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Matejak-G\u00f3rska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Durlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2021.03.008_bib0001","series-title":"Coronavirus (COVID-19) deaths worldwide per one million population as of March 23, 2021, by country","year":"2021"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0002","unstructured":"Poltransplant. Statistics 2020, http:\/\/www.poltransplant.org.pl\/statystyka_2020.html. 2020. [accessed 08.03.2021]."},{"key":"10.1016\/j.transproceed.2021.03.008_bib0003","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/ndt\/gfaa261","article-title":"COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration","volume":"35","author":"Hilbrands","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0004","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0005","unstructured":"Adaptive COVID-19 Treatment Trial 2 ClinicalTrials.gov Identifier: NCT04401579."},{"key":"10.1016\/j.transproceed.2021.03.008_bib0006","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0007","unstructured":"Efficacy of Nafamostat in COVID-19 Patients (RACONA Study) (RACONA) ClinicalTrials.gov Identifier: NCT04352400."},{"key":"10.1016\/j.transproceed.2021.03.008_bib0008","series-title":"FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment, another achievement in administration's fight against pandemic","year":"2020"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0009","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/jmv.25882","article-title":"Treatment with convalescent plasma for COVID-19 patients in Wuhan","volume":"92","author":"Ye","year":"2020","journal-title":"China. J Med Virol"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0011","doi-asserted-by":"crossref","unstructured":"Gharbharan A, Jordans CCE, Geurtesvankessel C, den Hollander JG, Faiz Karim, Mollema FPM, et\u00a0al. Convalescent plasma for COVID-19. A randomized clinical trial [e-pub ahead of print]. medRxiv doi:10.1101\/2020.07.01.20139857, [accessed 22.02.2021].","DOI":"10.1101\/2020.07.01.20139857"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0012","doi-asserted-by":"crossref","first-page":"m4072","DOI":"10.1136\/bmj.m4072","article-title":"Convalescent plasma is ineffective for COVID-19","volume":"371","author":"Pathak","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0013","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in COVID-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0014","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing antibody LY-CoV555 in outpatients with COVID-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0016","series-title":"Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19","year":"2021"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0017","series-title":"Emergency use authorization 094","year":"2021"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0018","series-title":"Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19","year":"2020"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0019","unstructured":"US Food and Drug Administration. Regeneron Pharmaceuticals, Inc,https:\/\/www.fda.gov\/media\/143891\/download. 2020. [accessed 08.03.2021]."},{"key":"10.1016\/j.transproceed.2021.03.008_bib0020","series-title":"EMA issues advice on use of antibody combination (bamlanivimab \/etesevimab)","year":"2021"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0021","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","article-title":"Remdesivir: first approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0022","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0023","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe COVID-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0024","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0025","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0026","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0027","series-title":"Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment","year":"2020"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0028","doi-asserted-by":"crossref","unstructured":"Rosas I, Br\u00e4u I, Waters M, Go RC, Hunter BD, Bhagani S, et\u00a0al. Tocilizumab in hospitalized patients with COVID-19 pneumonia [e-pub ahead of print]. medRxiv doi:10.1101\/2020.08.27.20183442, [accessed 22.02.2021].","DOI":"10.1056\/NEJMoa2028700"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14787210.2020.1800453","article-title":"Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study","volume":"19","author":"Tomasiewicz","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0030","series-title":"No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY","year":"2020"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0031","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0032","doi-asserted-by":"crossref","unstructured":"Yin S, Huang M, Li D, Tang N: Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 [e-pub ahead of print]. J Thromb Thrombolysis doi:10.1007\/s11239-020-02105-8, [accessed 17.01.2021].","DOI":"10.1007\/s11239-020-02105-8"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0033","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0034","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0035","doi-asserted-by":"crossref","first-page":"E2665","DOI":"10.3390\/jcm9082665","article-title":"Clinical profiles in renal patients with COVID-19","volume":"9","author":"Arenas","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0036","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1681\/ASN.2020050639","article-title":"COVID-19 infection in kidney transplant recipients: disease incidence and clinical outcomes","volume":"31","author":"Elias","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0037","doi-asserted-by":"crossref","first-page":"e13381","DOI":"10.1111\/tid.13381","article-title":"COVID-19 infection in solid organ transplant recipients: a single-center experience with patients immediately after transplantation","volume":"23","author":"Kolonko","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0038","article-title":"Recommendations for immunosuppressive treatment after vascularized organ transplantation","author":"Durlik","year":"2018","journal-title":"Warsaw, Poland: Polish Transplant Society;"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0039","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/ndt\/gfw086","article-title":"Efficacy and safety of antibody induction therapy in the current era of kidney transplantation","volume":"31","author":"Opelz","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0040","doi-asserted-by":"crossref","unstructured":"Del Bello A, Marion O, Sallusto F, Delas A, Esposito L, Doumerc N, et\u00a0al. Kidney transplantation during the COVID-19 pandemic: potential long-term consequences of an early post-transplant infection [e-pub ahead of print]. Transpl Infect Dis doi:10.1111\/tid.13446, [accessed 17.01.2021].","DOI":"10.1111\/tid.13446"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0041","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1111\/ajt.16261","article-title":"Evidence of potent humoral immune activity in COVID19-infected kidney transplant recipients","volume":"20","author":"Hartzell","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0042","doi-asserted-by":"crossref","unstructured":"Kates OS, Haydel BM, Florman SS, Rana MM, Chaudhry ZS, Ramesh MS, et\u00a0al. COVID-19 in solid organ transplant: a multi-center cohort study [e-pub ahead of print]. Clin Infect Dis doi:10.1093\/CID\/CIAA1097, [accessed 17.01.2021].","DOI":"10.1093\/cid\/ciaa1097"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0043","doi-asserted-by":"crossref","first-page":"e13421","DOI":"10.1111\/tid.13421","article-title":"COVID-19 in solid organ transplant recipients: no difference in survival compared to general population","volume":"23","author":"Rinaldi","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0044","doi-asserted-by":"crossref","first-page":"e13451","DOI":"10.1111\/tid.13451","article-title":"Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy","volume":"23","author":"Naeem","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2021.03.008_bib0045","doi-asserted-by":"crossref","first-page":"e14025","DOI":"10.1111\/ctr.14025","article-title":"Convalescent plasma therapy: helpful treatment of COVID-19 in a kidney transplant recipient presenting with severe clinical manifestations and complex complications","volume":"34","author":"Jiang","year":"2020","journal-title":"Clin Transplant"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134521001962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134521001962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:37:43Z","timestamp":1758577063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134521001962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0041134521001962"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.03.008","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}